ArticleMethods in molecular biology (Clifton, N.J.)2025
Native and Endogenous SUMO Site Identification Using Mass Spectrometry (NESSI-MS).
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small Ubiquitin-like Modifiers (SUMOs) are an important class of post-translational modification (PTM), modifying target proteins and thereby regulating virtually all nuclear processes. Various proteomics methods exist for profiling SUMO target proteins or SUMOylated lysine residues in a systemic manner, typically based on purification of SUMO followed by mass spectrometry (MS), with most approaches relying on ectopically expressed or mutant SUMO. However, to properly understand the role of SUMO in the context of health and disease, it is necessary to study native and endogenous SUMOylation, rather than relying on genetically engineered systems. Here, we present Native and Endogenous SUMOylation Site Identification using Mass Spectrometry (NESSI-MS), an MS-based proteomics strategy, which entails antibody-based purification of peptides bearing endogenous SUMO2/3 and allows exact mapping of the SUMOylated lysine residues using mass spectrometry.
Indexed as
Identifiers
40875113What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.